Study of Biochemical Changes during Treatment of Kidney Stone and Urinary Tract Infection with Herbal Drug
DOI:
https://doi.org/10.61841/45q8mq26Keywords:
Urinary Tract Infection, Kidney Stone, Herbal DrugsAbstract
A fewer communal category of pebble is produced by the contamination in the urinary area. This pebble is termed a contamination pebble. The herbal drug has remained well-known for eras and is vastly valued everywhere in the ecosphere as an abundant basis of healing representatives for the anticipation of several illnesses. The current investigation was to test the biochemical test finding before and after therapy with herbal drugs in patients with kidney stones and UTIs. The investigation was based on 210 cases of kidney disorders in the medical lab center, from which 105 were suffering from kidney stones, and 105 were with urinary tract infections. Urine and blood samples were collected from them for conducting blood biochemical parameters and serological tests for UTI. The patients took an average of 6 tablets a day, corresponding to standard dosage procedures. Before treatment, the kidney stone groups were compared concerning the severity of stone disease with the control group. The group stone formation rates were found to have an insignificant difference with that of the control group. In the case of the ‘Serum Glucose' level, it was found to have a significant difference between the before and control groups (89.742±1.074 and 85.81±5.63). In the current study, the positive connection between biochemical parameters and herbal drugs and allopathic drug therapy stretches maintenance to the rate of recovery in both kidney stones and UTIs. The upcoming natural herbal yields will be challenging new drugs through additional benefits of added protection as well as lesser prices.
Downloads
References
[1] O.W. Moe. Kidney stones: pathophysiology and medical management. The lancet, 367(9507), 2006, 333-
344.
[2] G.C. Curhan, W.C. Willett, E.L. Knight, M.J. Stampfer. Dietary factors and the risk of incident kidney
stones in younger women: Nurses' Health Study II. Archives of Internal Medicine, 164(8), 2004, 885-891.
[3] D.W. Killilea, J.L. Westropp, R. Shiraki, M. Mellema, J. Larsen, A.J. Kahn, M.L. Stoller. Elemental
content of calcium oxalate stones from a canine model of urinary stone disease. PloS one, 10(6), 2015,
e0128374.
[4] O. Devuyst, Y. Pirson. Genetics of hypercalciuric stone-forming diseases. Kidney international, 72(9),
2007, 1065-1072.
[5] D.S. Goldfarb. Nephrolithiasis. Annals of internal medicine, 151(3), 2009, ITC2-1.
[6] J.H. Parks, M. Coward, F.L. Coe. Correspondence between stone composition and urine super saturation in
nephrolithiasis. Kidney International, 51(3), 1997, 894-900.
[7] J.H. Parks, M. Coward, F.L. Coe. Correspondence between stone composition and urine super saturation in
nephrolithiasis. Kidney international, 51(3), 1997, 894-900.
[8] S.R. Khan, M.S. Pearle, W.G. Robertson, G. Gambaro, B.K. Canales, S. Doizi, H.G. Tiselius. Kidney
stones. Nature Reviews Disease Primers, 2, 2016, 16008.
[9] V.K. Sigurjonsdottir, H.L. Runolfsdottir, O.S. Indridason, R. Palsson, V.O. Edvardsson. Impact of
nephrolithiasis on kidney function. BMC nephrology, 16(1), 2015, 149.
[10] Z.M. El-Zoghby, J.C. Lieske, R.N. Foley, E.J. Bergstralh, , X. Li, , L.J. Melton, A.D. Rule. Urolithiasis and
the risk of ESRD. Clinical Journal of the American Society of Nephrology, 2012, CJN-03210312.
[11] B.R. Waterman, B.D. Owens, S. Davey, M.A. Zacchilli, P.J. BelmontJr. The epidemiology of ankle sprains
in the United States. JBJS, 92(13), 2010, 2279-2284.
[12] T.M. Hooton. Uncomplicated urinary tract infection. New England Journal of Medicine, 366(11), 2012,
1028-1037.
[13] G.R. Nielubowicz, H.L. Mobley. Host–pathogen interactions in urinary tract infection. Nature Reviews
Urology, 7(8), 2010, 430.
[14] B. Foxman. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and
disease burden. Infectious disease clinics of North America, 28(1), 2014, 1-13.
[15] T.J. Hannan, M. Totsika, K.J. Mansfield, K.H. Moore, M.A. Schembri, S.J. Hultgren. Host–pathogen
checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli
bladder infection. FEMS microbiology reviews, 36(3), 2012, 616-648.
[16] Kostakioti, M., Hultgren, S.J., & Hadjifrangiskou, M. (2012). Molecular blueprint of uropathogenic
Escherichia coli virulence provides clues toward the development of anti-virulence
therapeutics. Virulence, 3(7), 592-593.
[17] S. Subashchandrabose, T.H. Hazen, A.R. Brumbaugh, S.D. Himpsl, S.N. Smith, R.D. Ernst, H.L. Mobley.
Host-specific induction of Escherichia coli fitness genes during human urinary tract infection. Proceedings
of the National Academy of Sciences, 111(51), 2014, 18327-18332.
[18] R. Rajavel, P. Mallika, V. Rajesh, K. Pavan Kumar, S. Krishna Moorthy, T. Sivakumar. Antinociceptive
and Antiinflammatory Effects of the Methanolic extract of Oscillatoria annae. Res J Chem Sci, 2(7), 2012,
53-61.
[19] M. Ahmed, B.K. Datta, & A.S.S. Rouf. Rotenoids from Boerhaavia repens. Phytochemistry, 29(5), 1900,
1709-1710.
[20] N. Lami, S. Kadota, Y. Tezuka, & T. Kikuchi. Constituents of the Roots of Boerhaavia diffusa L. II.:
Structure and Stereochemistry of a New Rotenoid, Boeravinone C. Chemical and Pharmaceutical
Bulletin, 38(6), 1900, 1558-1562.
[21] S. Kadota, N. Lami,Y. Tezuka, & T. Kikuchi. Constituents of the Roots of Boerhaavia diffusa LI:
Examination of Sterols and Structures of New Rotenoids, Boeravinones A and B. Chemical and
Pharmaceutical Bulletin, 37(12), 1989, 3214-3220.
[22] N. Lami, S. Kadota, T. Kikuchi. Constituents of the roots of Boerhaavia diffusa L. IV. Isolation and
structure determination of boeravinones D, E, and F. Chemical and Pharmaceutical Bulletin, 39(7), 1991,
1863-1865.
[23] R.K. Seth, M. Khanna, M. Chaudhary, S. Singh, J.P.S. Sarin. Estimation of punarnavosides, a new
antifibrinolytic compound from Boerhaavia diffusa. Indian Drugs, 23(10), 1986, 583-4.
[24] N.L. Oburai, V.V. Rao, R.B.N. Bonath. Comparative clinical evaluation of Boerhavia diffusa root extract
with standard Enalapril treatment in Canine chronic renal failure. Journal of Ayurveda and integrative
medicine, 6(3), 2015, 150.
[25] S.K. Pareta, K.C. Patra, P.M. Mazumder, D. Sasmal. Aqueous extract of Boerhaavia diffusa root
ameliorates ethylene glycol-induced hyperoxaluric oxidative stress and renal injury in rat
kidney. Pharmaceutical biology, 49(12), 2009, 1224-1233.
[26] J.P. Mishra. Studies on the effect of indigenous drug Boerhaavia diffusa Rom. on kidney
regeneration. Indian Journal of Pharmacy, 12(59), 1980, 1487-98.
[27] T. Alelign, B. Petros. Kidney Stone Disease: An Update on Current Concepts. Advances in urology, 2018.
[28] A.L. Flores-Mireles, J.N. Walker, M. Caparon, S.J. Hultgren. Urinary tract infections: epidemiology,
mechanisms of infection and treatment options. Nature reviews microbiology, 13(5), 2015, 269.
[29] A.R. Mahesh, H. Kumar, M.K. Ranganath, R.A. Devkar. Detail study on Boerhaavia diffusa plant for its
medicinal importance-A Review. Research Journal of Pharmaceutical Sciences, 1(1), 2012, 28-36.
[30] M.L. Wilson, L. Gaido. Laboratory diagnosis of urinary tract infections in adult patients. Clinical infectious
diseases, 38(8), 2004, 1150-1158.
[31] V. Gohil Unnati, M. Vipul, M.V. Patel, S.N. Gupta, K.B. Patel. Polyherabal Treatment for Chronic Kidney
Disease – A Case Study. Universal Journal of Pharmacy. 02 (04), 2013, 44-47.
[32] D.Barham, P. Trinder. An improved colour reagent for the determination of blood glucose by the oxidase
system. Analyst, 97(1151), 1972, 142-145.
[33] NW Tietz. Clinical guide to laboratory test. 2006. 4th ed. p. 1096- 1099.
[34] D. Labbe, A. Vassault, B. Cherruau, P. Baltassat, R. Bonete, G. Carroger, A. Nicolas. Method selected for
the determination of creatinine in plasma or serum. Choice of optimal conditions of measurement. In
Annales de biologie Clinique, 54(8), 1996, pp. 285-298).
[35] R.J. Henry, D.C. Cannon, J.W. Winkelman. Principles and techniques. Clinical Chemistry, 2nd Ed. Harper
and Row, 1974, 525.
[36] N.W. Tietz. Fundamentals of Clinical Chemistry, Saunders, Philadelphia, 2006, 4th Edit., 984.
[37] J. Stern, W.H.P. Lewis. The colorimetric estimation of calcium in serum with O-cresolphthalein
complexone. Clinica Chimica Acta, 2(6), 1957, 576-580.
[38] E.S. Baginski, P.P. Foa, B. Zak. Determination of phosphate: study of labile organic phosphate
interference. Clinica Chimica Acta, 15(1), 1967, 155-158.
[39] P. Trinder. Determination of glucose in blood using glucose oxidase with an alternative oxygen
acceptor. Annals of clinical Biochemistry, 6(1), 1969, 24-27.
[40] C.C. Allain, L.S. Poon, C.S. Chan, W.F.P.C. Richmond, P.C. Fu. Enzymatic determination of total serum
cholesterol. Clinical chemistry, 20(4), 1974, 470-475.
[41] P. Fossati. Prencipe. L. Serum TG determination colorimeterically with on enzyme that produces
inflammatory reaction. Am. j. pathol, 1982, 107-397.
[42] M.T. Yakubu, L.S. Bilbis, M. Lawal, M.A. Akanji. Evaluation of selected parameters of rat liver and
kidney function following repeated administration of yohimbine. Biokemistri, 15(2), 2003, 50-56.
[43] B.L. Craven, C. Passman,D. G. Assimos. Hypercalcemic states associated with nephrolithiasis. Reviews in
urology, 10(3), 2008, 218.
[44] M. Daudon, O. Traxer, P. Conort, B. Lacour, P. Jungers. Type 2 diabetes increases the risk for uric acid
stones. Journal of the American Society of Nephrology, 17(7), 2006, 2026-2033.
[45] H.S. Chen, L.T. Su, S. Z. Lin, F.C. Sung, M.C. Ko, C.Y. Li. Increased risk of urinary tract calculi among
patients with diabetes mellitus—a population-based cohort study. Urology, 79(1), 2012, 86-92.
[46] B.J. Ansell, K.E. Watson, A.M. Fogelman, M. Navab, G.C. Fonarow. High-density lipoprotein function:
recent advances. Journal of the American College of Cardiology, 46(10), 2005, 1792-1798.
[47] N. Johnkennedy, O. Chinedu, N. Richard, I. Chinedu, O. Chinyere, E. Ukamaka. Investigations on serum
lipid profile in patients with urinary tract infections. Global Journal of Scientific Researches, 1(3), 2013,
68-70.
[48] C. Alvarez, A. Ramos. Lipids, lipoproteins, and apoproteins in serum during infection. Clinical
chemistry, 32(1), 1986, 142-145.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 AUTHOR
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
